Biomarkers and Prediction of Tigecycline Induced Coagulation Dysfunction
Launched by THE AFFILIATED NANJING DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL · Jan 16, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how the antibiotic tigecycline can affect blood clotting in patients. Researchers want to identify specific markers in the body (called biomarkers) that can help predict if someone will experience problems with blood coagulation while being treated with tigecycline. This is important because finding these markers could help doctors better manage the treatment and reduce risks for patients.
To participate in this study, patients must be hospitalized and receiving tigecycline for at least three days. They also need to have their tigecycline levels monitored during treatment. This trial is open to all genders and is looking specifically at patients between the ages of 65 and 74. Since the trial is not yet recruiting participants, there will be more information available in the future about what to expect during the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Inpatients receiving tigecycline treatment in the Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- • Intravenous tigecycline ≥ 3 days
- • Monitoring the plasma concentration of tigecycline
- Exclusion Criteria:
- • Missing clinical data
About The Affiliated Nanjing Drum Tower Hospital Of Nanjing University Medical School
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School is a leading academic medical institution in China, renowned for its commitment to advanced healthcare, research, and medical education. As a prominent sponsor of clinical trials, the hospital leverages its state-of-the-art facilities and multidisciplinary expertise to facilitate innovative medical research aimed at improving patient outcomes. With a focus on translational medicine, the institution fosters collaborations between clinicians and researchers to accelerate the development of novel therapies and enhance the understanding of complex diseases. Through its rigorous adherence to ethical standards and regulatory compliance, the hospital is dedicated to advancing medical knowledge and contributing to the global scientific community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials